why choose us

First received: April 26, 2023

Clinical Trial: A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Relapsed/Refractory Multiple Myeloma

Study Type: INTERVENTIONAL


Official Title: A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma

Brief Summary: This is a research study to find out if a drug called belantamab mafodotin in combination with dexamethasone, a steroid, can be safely and effectively given in the community setting.Belantamab mafodotin (BLENREP) was approved in the US in August 2020 under an FDA program called accelerated approval.In November 2022, belantamab mafodotin was removed from the market because a study to further confirm its activity in relapsed/refractory multiple myeloma did not deliver a supporting result.However, this…

Read more